The Board resolution dated December 13, 2021, the BOD of Cuu Long Pharmaceutical Joint Stock Company approved the following issues:

1)      Approving the purchase of shares of Benovas Medevices due to Benovas Medevices offers shares to existing shareholders:

-          Current owning volume: 3,075,000 shares, accounting for 61.5% of current charter capital of Benovas Medevices

-          Number of shares offered according to the Resolution of the Extraordinary General Meeting of Shareholders dated November 01, 2021 of Benovas Medevices: 3,075,000 shares

-          Number of shares receiving priority right to buy shares from VPC – SG Pharma and Benovas Pharma: 1,925,000 shares.

-          Total number of shares purchased from the offering to existing shareholders of Benovas Medevices: 5,000,000 shares

-          Total number of shares owned after the additional purchase: 8,075,000 shares, accounting for 80.75% of current charter capital of Benovas Medevices after the issuance.

-          Par value: VND10,000/share

-          Purchase price: VND10,000/share

-          Time of implementation: Quarter IV/2021 – Quarter I/2022

-          Using capital resources: to use from the proceeds from the share private placement.

2)      Approving the purchase of shares of Benovas Pharma due to Benovas Pharma offers shares to existing shareholders:

-          Current owning volume: 2,850,000 shares, accounting for 95% of current charter capital of Benovas Pharma

-          Number of shares offered according to the Resolution of the Extraordinary General Meeting of Shareholders dated November 02, 2021 of Benovas Pharma: 4,750,000 shares

-          Number of shares receiving priority right to buy shares from Pham Thi Bich Dao and Tran Van Loi: 250,000 shares

-          Total number of shares purchased from the offering to existing shareholders of Benovas Pharma: 5,000,000 shares

-          Total number of shares owned after the additional purchase: 7,850,000 shares, accounting for 98.13% of current charter capital of Benovas Pharma after the issuance.

-          Par value: VND10,000/share

-          Purchase price: VND10,000/share

-          Time of implementation: Quarter IV/2021 – Quarter I/2022

-          Using capital resources: to use from the proceeds from the share private placement.